Washington University

The Johns Hopkins University

G.d. Searle & Company

Other

Neuraxis, LLC

Matatu, Inc.

Neuraxis Technologies LLC

Intercontinental Great Brands LLC

Jeffrey I Gordon

Steven P Adams

George W Gokel

Paul T Englund

Robert O Heuckeroth

Balekudru Devadas

Daniel P Getman

James A Sikorski

David Louis Brown

Srinivasan Raj Nagarajan

Peter O Olins

David K Hayashi

Mark E Zupec

Dwight A Towler

Ryan M Kretzer

Bryan W Cunningham

Robert J Duronio

Barbara Lyle

Peggy Martini

Joseph K Welply

Ansel Hsiao

Andrew C Serazin

Per Falk

Emily M Garabedian

Devadas Balekudru

Nathaniel McNulty

Sathish Subramanian

Peter Turnbaugh

The present technology encompasses systems for predicting a characteristic of an individual subject, as well as methods for predicting a characteristic of a particular subject based on the systems of the technology disclosed herein. The disclosure herein also provides methods to improve a characteristics in a subject, based on the prediction produced by the system.

Use of a gut microbiome as a predictor of animal growth or health

The present invention provides a method to define normal maturation of the gut microbiota using a limited number of bacterial taxa found in the gut microbiota. Regressing the relative abundance of age-discriminatory taxa in their gut microbiota against the chronological age of each healthy subject at the time a sample of the gut microbiota was collected produces a regression model that may be used to characterize the maturity of another subject's gut microbiota to provide a measure of gastrointestinal health without having to query the whole microbiota. The present invention also provides composition and methods for preventing and/or treating a disease in a subject in need thereof.

Methods to establish and restore normal gut microbiota function of subject in need thereof

Compression-distraction spinal fixation systems, and methods of performing compression-distraction spinal fixation, are provided that include screw-rod constructs having a ratcheting mechanism. Bone screws of the screw-rod constructs can have a pawl that engages ratchet teeth on the rod of the screw-rod construct. The bone screw can be unidirectionally ratcheted along the length of the rod to apply compressive or distractive forces. Tools for manipulation of the screw-rod constructs are also provided, which tools include distal tips configured to engage the bone screws.

Compression-distraction spinal fixation system and kit

Compression-distraction spinal fixation systems, and methods of performing compression-distraction spinal fixation, are provided that include screw-rod constructs having a ratcheting mechanism. Bone screws of the screw-rod constructs can have a pawl that engages ratchet teeth on the rod of the screw-rod construct. The bone screw can be ratcheted along the length of the rod to apply distractive or compressive forces.

Compression-distraction spinal fixation system

Seryl-lysyl-based peptide and peptidomimetic inhibitors of N-myristoyl transferase as anti-infective agents

A method of inhibiting parasitic activity is disclosed in which the biosynthesis, structure and/or function of the glycosyl phosphatidylinositol (GPI) anchor of said parasite may be affected by incorporating into said GPI anchor selected analogs of myristic acid containing various heteroatoms, substituents and unsaturated bonds, including ester-containing analogs, ketocarbonyl-containing analogs, sulfur-containing analogs, double bond- and triple bond-containing analogs, aromatic moiety-containing analogs, nitrated analogs and halogenated analogs.

Furyl containing fatty acids, glycosyl phosphatidylinositol (GPI)

Method of inhibiting parasitic activity

Thienyl-containing fatty acid glycosyl phosphatidylinosital analogues

Novel oxy- and thio-substituted fatty acid analog substrates of myristoylating enzymes are provided which contain an oxygen or sulfur in place of a methylene group in a carbon position from 4 to 13 in the fatty acid chain of a C.sub.13 -C.sub.14 fatty acid or alkyl ester thereof.

Fatty acid analog enzyme substrates

Seryl-lysyl-based peptide and peptidomimetic compounds are described as inhibitors of the enzyme N-myristoyl transferase to provide selective control of the fungal organism Candida albicans. Peptidomimetic compounds of particular interest are those of the formula: ##STR1## wherein R.sup.1 is selected form aminoalkyl, p-aminoalkylphenylalkyl, imidazolylalkylphenylalkyl, 2-alkylimidazolylalkylphenylalkyl, benzimidazolylalkylphenylalkyl and 2-alkylbenzimidazolylalkylphenylalkyl; wherein R.sup.2 is selected from hydrido, alkyl, cycloalkyl, akenyl, alkynyl, haloalkyl, benzyl, alkylphenylalkyl, alkoxyphenylalkyl, halophenylalkyl, phenethyl, cycloalkylalkyl, halocycloalkylalkyl, alkylcycloalkylalkyl, alkoxycycloalkylalkyl and naphthylalkyl; wherein Y is selected from carboxylic acid, hydroxamic acid, phosphonic acid and tetrazolyl; or a pharmaceutically-acceptable salt, amide or ester thereof. Compounds of the formula are species-specific inhibitors of C. albicans with little effect on human NMT enzyme and thus would be useful in treating C. albicans fungal infections in humans.

Seryl-lysyl-based peptide and peptidomimetic inhibitors of N-myristoyl

Disclosed are transgenic mice that produces prostate tumors and faithfully recapitulate many of the features of human prostatic carcinoma. It has been discovered that transcriptional regulatory elements active in Paneth cells, granule goblet cells, intermediate cells, or a combination, when used to express Simian Virus 40 large T antigen (TAg) in a transgenic mouse leads to development of prostate tumors in the mouse. The transcriptional regulatory elements are derived from the cryptdin-2 (CR2) gene. The disclosed mice develop prostatic intraepithelial neoplasia (PIN) at an early age. Progression with local invasion, loss of androgen-dependence and eventual metastases are hallmarks of the disclosed transgenic mice. Preferred embodiments of the disclosed transgenic mice have several important characteristics: (1) the disease is fully penetrant--all mice containing the SV40 TAg transgene develop prostatic cancer; (2) the first appearance of SV40 TAg always coincides with the appearance of cellular atypia in prostatic acini; (3) the rate of progression of the neoplasia is rapid; (4) prostatic adenocarcinomas in the transgenic mice exhibit foci of neuroendocrine differentiation; (5) metastatic lesions are common in the lymph nodes, liver, lung, and bone of the disclosed transgenic mice and are evident early in life; and (6) the lifespan of the disclosed transgenic animals is not shortened by transgene-related pathology in other organs--female transgenic mice develop normally and have a normal lifespan.

Transgenic mouse model of prostate cancer

A method of inhibiting parasitic activity is disclosed in which the biosynthesis, structure and/or function of the glycotyl phosphatidylinositol (GPI) anchor of said parasite may be affected by incorporating into said GPI anchor selected analogs of myristic acid containing various heteroatoms, substituents and unsaturated bonds, including ester-containing analogs, ketocarbonyl-containing analogs, sulfur-containing analogs, double bond- and triple bond-containing analogs, aromatic moiety-containing analogs, nitrated analogs and halogenated analogs.

Tetradecadienoic acid, a glycosyl phosphatidylinositol (GPI) analogue

Growing community of inventors

Olivette, MO, United States of America

Jeffrey I Gordon